Obesity triggers tumoral senescence and renders poorly immunogenic malignancies amenable to senolysis.
Sign Up to like & getrecommendations! Published in 2022 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.2209973120
Abstract: Obesity is a major risk factor for cancer. Conventional thought suggests that elevated adiposity predisposes to heightened inflammatory stress and potentiates tumor growth, yet underlying mechanisms remain ill-defined. Here, we show that tumors from patients… read more here.
Keywords: immunogenic malignancies; poorly immunogenic; senescence; obesity ... See more keywords
Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors
Sign Up to like & getrecommendations! Published in 2018 at "OncoImmunology"
DOI: 10.1080/2162402x.2018.1457596
Abstract: ABSTRACT Activation of immune checkpoint pathways and limited T- cell infiltration result in immunological escape of tumors. Although immune checkpoint inhibitors are currently approved for several types of cancers, the response rate is often limited… read more here.
Keywords: response; immunogenic tumors; rate; poorly immunogenic ... See more keywords
In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models
Sign Up to like & getrecommendations! Published in 2021 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-002432
Abstract: Background Dendritic cells (DCs) are a promising therapeutic target in cancer immunotherapy given their ability to prime antigen-specific T cells, and initiate antitumor immune response. A major obstacle for DC-based immunotherapy is the difficulty to… read more here.
Keywords: dcs; ipsc dcs; poorly immunogenic; antitumor ... See more keywords
Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-004781
Abstract: Background Single-agent immunotherapy has shown remarkable efficacy in selected cancer entities and individual patients. However, most patients fail to respond. This is likely due to diverse immunosuppressive mechanisms acting in a concerted way to suppress… read more here.
Keywords: immunogenic tumors; combination immunotherapy; immunotherapy; antigen agnostic ... See more keywords